In vitro interaction of HMG-CoA reductase inhibitors (statins) with MDR1, MRP2, and OATP-C

被引：0
|
作者：
Chen, CP [1 ]
Mireles, R [1 ]
Campbell, S [1 ]
Lin, J [1 ]
Mills, J [1 ]
Xu, J [1 ]
Smolarek, T [1 ]
机构：
[1] Pfizer Inc, Groton Lab, Groton, CT 06340 USA
来源：
DRUG METABOLISM REVIEWS | 2003年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
303
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [21] Functional characterization of MRP2 allelic variants using OATP-C/MRP2 double-transfected HeLa cells
    Ho, RH
    Leake, BF
    Kim, RB
    PEDIATRIC RESEARCH, 2003, 53 (04) : 276A - 276A
  • [22] OVERLAP AND DIFFERENCES IN THE INHIBITION OF HUMAN OATP1B1, OATP1B3, MDR1, AND MRP2 BY REGISTERED DRUGS IN VITRO
    Van de Steeg, Evita
    Vlaming, Maria L. H.
    Jansen, Harm T.
    Nooijen, Irene H. G.
    Schrander, Freek L.
    DeGroot, Jeroen
    Wortelboer, Heleen M.
    DRUG METABOLISM REVIEWS, 2012, 44 : 77 - 77
  • [23] pH-Sensitive Interaction of HMG-CoA Reductase Inhibitors (Statins) with Organic Anion Transporting Polypeptide 2B1
    Varma, Manthena V.
    Rotter, Charles J.
    Chupka, Jonathan
    Whalen, Kevin M.
    Duignan, David B.
    Feng, Bo
    Litchfield, John
    Goosen, Theunis C.
    El-Kattan, Ayman F.
    MOLECULAR PHARMACEUTICS, 2011, 8 (04) : 1303 - 1313
  • [24] Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
    Benoit Chauvin
    Sylvain Drouot
    Aurélie Barrail-Tran
    Anne-Marie Taburet
    Clinical Pharmacokinetics, 2013, 52 : 815 - 831
  • [25] ALLEVIATION OF SIDE-EFFECTS OF ANTICANCER THERAPEUTICS BY HMG-COA REDUCTASE INHIBITORS (STATINS)
    Damrot, Julia
    Ostrau, Christian
    Huelsenbeck, Johannes
    Herzog, Melanie
    Nuebel, Tobias
    Kaina, Bernd
    Fritz, Gerhard
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3284 - 3285
  • [26] HMG-CoA reductase inhibitors (statins) and bone mineral density: A meta-analysis
    Liu, Jie
    Zhu, Li-Ping
    Yang, Xu-Li
    Huang, He-Lang
    Ye, Dong-Qing
    BONE, 2013, 54 (01) : 151 - 156
  • [27] HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview
    Balasubramanian, Rajkapoor
    Maideen, Naina M. P.
    CURRENT DRUG METABOLISM, 2021, 22 (05) : 328 - 341
  • [28] IDENTIFYING PRIMARY NON-ADHERENCE RATES OF HMG-COA REDUCTASE INHIBITORS (STATINS)
    Lu, J.
    Suh, K.
    Hardisty, J.
    Bullano, M.
    Godley, P. J.
    VALUE IN HEALTH, 2013, 16 (03) : A290 - A290
  • [29] Functional characterization of MRP2 allelic variants using OATP-C/MRP2 double-transfected hela cells.
    Ho, RH
    Leake, BF
    Kim, RB
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P59 - P59
  • [30] HMG-COA reductase inhibitors (statins) increase the expression of COX-2 in gallbladder epithelial cells
    Choi, Min Ho
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A33 - A33
12345